Short duration neoadjuvant chemotherapy followed by radiotherapy for advanced carcinoma of the cervix: results and prognostic variables

Purpose: The value of neoadjuvant chemotherapy in squamous cell carcinomas of the cervix has not been proven. It has been suggested that the potential benefit of this therapy on local and occult metastatic disease could be offset by delaying effective radiation therapy and selection of more aggressive tumor clones. This report examines the potential impact of short duration neoadjuvant chemotherapy on the response and outcome of advanced carcinoma of the cervix.

Materials and methods: Between 1993 and 1997, 37 patients with advanced squamous cell carcinoma of the cervix (FIGO Stages IIB to IV) were enrolled in a prospective nonrandomized study using short duration neoadjuvant chemotherapy. Median age was 57 years (range: 34-70). Twenty-one patients (57%) had Stage IIB disease, one (3%) had Stage IIIA, 11 (30%) Stage IIIB, and four (11%) had Stage IV disease. The average tumor diameter at presentation assessed by physical examination and by CT scan measurements was 5.3 + 1.9 cm and 5.3 + 1.4 cm, respectively. Patients received three cycles of chemotherapy consisting of cisplatin 50 mg/m2 and vincristine 1 mg/m2 for 1 dose and bleomycin 25 mg/m2 daily for three days. Cycles were repeated every ten days. All patients started definitive radiotherapy within a week from the end of chemotherapy. Radiation therapy consisted of whole pelvis radiotherapy followed by 1-3 sessions of low dose rate brachytherapy.

Results: Response to neoadjuvant chemotherapy was as follows: seven patients (19%) had minor or no response, one patient had progressive disease, and 28 (76%) had more than 50% tumor reduction; 14 of them (38%) had no clinical evidence of residual tumor. Chemotherapy was discontinued in one patient after the second cycle because of significant changes in pulmonary function tests (PFT), and one patient developed a grade 4 urinary complication after radiotherapy. Median follow-up time for the whole group was 24 months (range: 1-67). Five-year actuarial rates of local control and disease-free survival were 47 and 42%, respectively. At three years, 20 patients (54%) were alive or had died without evidence of disease, and 17 (46%) had succumbed to their disease, with a median time to recurrence of 25 months. Stage and response to neoadjuvant chemotherapy had significant impact on survival, while age. tumor size, and menopausal status did not influence survival.

Conclusions: Our data indicate that short duration chemotherapy followed by definitive radiotherapy is well tolerated and feasible. However, despite a high rate of objective response (76%), and improved survival for responders, there was no obvious long-term survival benefit for the entire group.

Cervical cancer; Neoadjuvant chemotherapy; Radiotherapy

[1] Adelstein D. J., Saxton J.P., Lavertu P. et al.: "A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results". Head Neck, 1997, 19, 567.

[2] Adelstein D. J.: "Induction chemotherapy in head and neck cancer". Hematol. Oncol. Clin. No. Am., 1999, 13, 689.

[3] Bourhis J., Wilson G., Wibault P. et al.: "Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer". Laryngoscope, 1994, 104, 468.

[4] Bourhis J., Pignon J. P.: "Meta-analyses in head and neck squamous cell carcinoma. W hat is the role of chemotherapy?". Hematol. Oncol. Clin. No. Am., 1999, 13, 769.

[5] Chang T. C., Lai C. H., Hong J. H. et al.: "Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage 1B and II A cervical cancer". J. Clin. Oncol., 2000, 18, 1740.

[6] Chauvergne J., Rohart J., Heron J. F. et al.: "Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-Nl, T3b, MO)". Bull. Cancer, 1990, 77, 1007.

[7] Chauvergne J., Lhomme C., Rohart J. et al.: "Neoadjuvant chemotherapy of stage Ilb or III cancers of the uterine cervix. Longterm results of a multicenter randomized trial of 151 patients". Bull. Cancer, 1993, 80, 1069.

[8] Chiarugi V., Magnelli L., Chiarugi A. et al.: "Hypoxia induces pivotal tumor angiogenesis control factors including p53, vasculat endothelial growth factor and the NFkappaB-dependent inducible nitric oxide synthase and cyclooxygenase-2". J. Cancer. Res. Clin. Oncol., 1999, 125, 525.

[9] Eifel P. J., Morris M., Whatton J. T. et al.: "The influence of tumor size and morphology on the outcome of patients with FIGO stage 1B saqu amous cell carcinoma of the uterine cervix". Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 9.

[10] El-Sayed S., Nelson N.: "Adjuvant and adjunctive chemotherapy in the management of squamous cell catcinoma of the head and neck region. A meta-analysis of prospective and randomized trials". J. Clin. Oncol., 1996, 14, 838.

[11] Filtenborg T. A., Hansen H. H., Aage Engelholm et al.: "A phase II study of ifosfamide, carboplatin and cisplatin in advanced and recurrent squamous cell catcinoma of the uterine cervix". Ann. Oncol., 1993, 4, 485.

[12] Giaccia A. J.: "Hypoxic stress proteins". Sem. in Rad. One., 1996, 6, 46.

[13] Green J. A., Kirwan J. M., Tierney J. F. et al.: "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis". Lancet, 2001, 358 (9284), 781.

[14] Herscher L. L., Cook J. A., Pacelli R. et al.: "Principles of chemoradiation: theoretical and practical considerations". Oncology (Huntingt), 1999, 13 (Suppl. 5), I I.

[15] Jaulerry C., Rodriguez J., Brunin F. et al.: "Induction chemotherapy in advanced head and neck tumors: results of two randomized trials". Int. J. Radiat. Oncol. Biol. Phys., 1992, 23, 483.

[16] Horiot J. C., Pigneux J., Pourquier H. et al.: "Radiotherapy alone in Carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: a French cooperative study of 1383 cases". Int. J. Radiat. Oncol. Biol. Phys., 1988, 14, 605.

[17] Keys H. M., Bundy B. N., Stehman F. B. et al.: "Cisplatin, radiation and adjuvant hysterectomy compated with radiation and adjuvant hysterectomy for Bulky stage 1B cervical catcinoma". N. Engl. J. Med., 1999, 340, 1154.

[18] Kim D., Moon H., Hwang Y. et al.: "Preoperative adjuvant chemotherapy in the treatment of cervical cancer stage lb, Ila, and JIB with bulky tumor". Gynecol. Oneal., 1987, 29, 321.

[19] Kumat L., Kaushal R., Nandy M. et al.: "Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study". Gynecol. Oneal., 1994, 54, 307.

[20] Landis S. H., Murray T., Bolden S. et al.: "Cancer statistics, 1999". C. A. Cancer J. Clin., 1999, 49, 8.

[21] Leborgne F., Leborgne J. H ., Doldan R. et al.: "Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial". Int. J. Radiat. Oneal. Biol. Phys., 1997, 37, 343.

[22] Lehman M., Thomas G.: "Is concurrent chemotherapy and radiotherapy the new standard of cate for locally advanced cervical cancer?". Int. J. Gynecol. Cancer, 2001, 11, 87.

[23] Logsdon M. D., Eifel P. J.: "Figo IIIB squamous cell catcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy". Int. J. Radiat. Oneal. Biol. Phys., 1999, 43, 763.

[24] Mancuso S., Benedetti P., Greggi S.: "Neoadjuvant chemotherapy in advanced cervical catcinoma". Eur. J. Gynecol. Oncol., 1987, 8, 335.

[25] Mazeron J. J., Mattin M., Brun B. et al.: "Induction chemotherapy in head and neck cancer: results of a phase III trial". Head Neck, 1992, 14, 85.

[26] Merlano M., Benasso M., Corvo R. et al.: "Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell catcinoma of the head and neck". J. Natl. Cancer Inst., 1996, 88, 583.

[27] Morris M., Eifel P. J., Lu J. et al.: "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer". N. Engl. J. Med., 1999, 340, 1137.

[28] National Cancer Institute: "Concurrent chemotherapy for cervical cancer. Clinical announcement", Washington,D C,F ebruary 22,1999.

[29] Paccagnella A., Orlando A., Marchiori C. et al.: "Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo". J. Natl. Cancer. Inst., 1994, 86, 265.

[30] Pearcy R., Brundage M., Jeffrey J. et al.: "A clinical trial comparingconcnrrent cisplatin and radiation therapy vs. radiation therapy alone for locally advanced squamous cell carcinoma of the cervix acrried out by the National Cancer Institute of Canada Clinical Trials Group". Proc. Am. Soc. Clin. Oneal., 2000, 19, 378 (abstract).

[31] Perez C. A., Grigsby P. W., Chao K. S. et al.: "Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix". Int. J. Radiat. Oneal. Biol. Phys.,1998, 41, 307.

[32] Richard J. M., Sancho-Garnier H., Pessey J. J. et al.: "Randomized trial of induction chemotherapy in larynx carcinoma". Oral. Oneal., 1998, 34, 224.

[33] Roberts K. B., Urdaneta N., Vera R. et al.: "Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix". Int. J. Cancer, 2000, 90, 206.

[34] Rose P. G., Bundy B. N., Watkins E. B. et al.: "Concurrent cisplatin- based radiotherapy and chemotherapy for locally advanced cervical cancer". N. Engl. J. Med., 1999, 340, 1144.

[35] Rosenthal D. I., Pistenmaa D. A., Glatstein E.: "A review of neoadjuvant chemotherapy for head and neck cancer: partially shrunken tumors may be both leaner and meaner". Int. J. Radiat. Oneal. Biol. Phys., 1994, 28, 315.

[36] Rustin G. J., Newlands E. S., Southcott B. M. et al.: "Cisplatin, vincristine, methotrexate and bleomycin (POMB) as initial or palliative chemotherapy for carcinoma of the cervix". Br. J. Obstet. Gynaecol., 1987, 94, 1205.

[37] Sardi J., Di Paola G., Cachau A. et al.: "A possible new trend in the management of carcinoma of the cervix". Gynecol. Oneal., 1986, 25, 139.

[38] Sardi J.,S ananes C.,G iaroli A. et al.: "Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri". Gynecol. Oneal.,1990, 38, 486.

[39] Sardi J., Sananes C., Giaroli A. et al.: "Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix". Gynecol. Oneal., 1993, 49, 156.

[40] Sardi J. E., Giaroli A., Sananes C. et al.: "Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage lb squamous carcinoma of the cervix: the final results". Gynecol. Oneal., 1997, 67, 61.

[41] Seoud M., Shamsseddine A., Saghir N. et al.: "Gynecologic registry at the American University of Beirut 1983-1998. The Intemational Gynecologic Society of Cancer (abst.)". September 1999, Rome, Italy.

[42] Smith H. O., Stringer C. A., Kavanagh J. J. et al.: "Treatment of advanced or recurrent squamous cell carcinoma of the uterine cervix with mitomycin-C, bleomycin, and cisplatin chemotherapy". Gynecol. Oneal., 1993, 48, 11.

[43] Souhami L., Gil R. A., Allan S. E. et al.: "A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix". J. Clin. Oneal., 1991, 9, 970.

[44] Tattersall M. H., Ramirez C., Coppleson M.: "A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage IbIla cervical cancer patients with pelvic lymph node metastases". Gynecol. Oneal., 1992, 46, 176.

[45] Tattersall M. H.,L orvidhaya V.,V ootiprux V. et al.: "Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association". J. Clin. Oneal., 1995, 13, 444.

[46] Thomas G. M.: "Improved treatment for cervical cancer - concurrent chemotherapy and radiotherapy". N. Engl. J. Med., 1999, 340, 1198.

[47] Xu L., Xie K., Mukaida N. et al.: "Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells". Cancer Res., 1999, 59, 5822.